EMEA-002124-PIP01-17

Key facts

Active substance
Pexastimogene devacirepvec
Therapeutic area
Oncology
Decision number
P/0201/2017
PIP number
EMEA-002124-PIP01-17
Pharmaceutical form(s)
Suspension for injection
Condition(s) / indication(s)
Treatment of hepatocellular carcinoma
Route(s) of administration
Intratumoral use
Contact for public enquiries
Transgene S.A.
France
Tel. +33 388279155
E-mail: clinical.trials@transgene.fr
Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating